PC
FATE icon

Polar Capital’s Fate Therapeutics FATE Stock Holding History

Polar Capital’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-150,000
Closed -$2.33M – 291
2019
Q3 		$2.33M Hold
150,000
– – 0.02% 254
2019
Q2 		$3.04M Buy
150,000
+105,700
+239% +$1.9M 0.03% 245
2019
Q1 		$778K Buy
+44,300
New +$699K 0.01% 249

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
GH
Grosvenor Holdings Chicago, Illinois $512M AUM 19.57% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Polar Capital's FATE Position: Q4 2019 in Review

Polar Capital sold out of Fate Therapeutics (FATE) in Q4 2019, closing a stake of 150,000 shares — an estimated $2.33M sold.

Polar Capital first reported a position in FATE in Q1 2019 and held it in 3 quarters. The position peaked at $3.04M in Q2 2019. 147 funds tracked by Wall St. Rank hold FATE as of Q4 2019.

  • Polar Capital reported no remaining Fate Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Polar Capital sold 150,000 Fate Therapeutics shares in Q4 2019, an estimated $2.33M.
  • Polar Capital first reported a position in Fate Therapeutics in Q1 2019 and held it in 3 quarters.
  • Polar Capital's Fate Therapeutics position peaked at $3.04M in Q2 2019.
  • 147 funds tracked by Wall St. Rank held Fate Therapeutics as of Q4 2019.

Based on Polar Capital's 13F filing for Q4 2019, filed 14 Feb 2020.